Federal plan for prescriber education on opioids misses opportunities

Annals of Internal Medicine

Volumn 157, Issue 3, 2012, Pages 205-206

  Becker, William C ^a   Fiellin, David A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

ARTICLE; DRUG CONTROL; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; FUNDING; GOVERNMENT; HEALTH CARE POLICY; HUMAN; MEDICAL EDUCATION; OPIATE ADDICTION; PAIN; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84864828609     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-11-201206050-00448     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention. Drug overdose deaths-Florida, 2003-2009. MMWR Morb Mortal Wkly Rep. 2011;60:869-72. [PMID: 21734633]
2. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152:85-92. [PMID: 20083827]
3. McLellan AT, Turner BJ. Chronic noncancer pain management and opioid overdose: time to change prescribing practices [Editorial]. Ann Intern Med. 2010; 152:123-4. [PMID: 20083830]
4. Food and Drug Administration. Draft blueprint for prescriber education for long-acting/extended-release opioid class-wide risk evaluation and mitigation strategy; availability; request for comments. Federal Register. 2011. Accessed at www.gpo.gov/fdsys/pkg/FR-2011-11-07/pdf/2011-28669.pdf on 20 February 2012.
5. Office of National Drug Control Policy. Epidemic: responding to America's prescription drug abuse problem. 2011. Accessed at www.whitehouse.gov/sites /default/files/ondcp/policy-and-research/rx_abuse_plan.pdf on 20 February 2012.
6. Food and Drug Administration. Blueprint for Prescriber Continuing Education Program. Accessed at www.fda.gov/downloads/Drugs/DrugSafety /InformationbyDrugClass/UCM277916.pdf on 22 February 2012.
7. Meier B. Narcotic maker guilty of deceit over marketing. The New York Times. 11 May 2007. Accessed at www.nytimes.com/2007/05/11/business /11drug.html on 22 January 2012.
8. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301: 1367-72. [PMID: 19336712]
9. Institute of Medicine. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academies Pr; 2009.
10. American Medical Association. Report 1 of the Council on Ethical and Judicial Affairs (A-11). 2011. Accessed at www.ama-assn.org/resources/doc/ethics /ceja-1a11.pdf on 28 January 2012.
11. Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academies Pr; 2007.
12. Waiver authority for physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment. H.R. 4365; 2000: 122-7. Accessed at buprenorphine. samhsa. gov/fulllaw. html on 22 January 2012.
13. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
14. Egan JE, Casadonte P, Gartenmann T, Martin J, McCance-Katz EF, Netherland J, et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010;25:936-41. [PMID: 20458550]
15. Holmboe ES. Assessment of the practicing physician: challenges and opportunities. J Contin Educ Health Prof. 2008;28 Suppl 1:S4-10. [PMID: 19058254]